- Research Scientist
- Professor, BIO5 Institute
- Professor, Medicine - (Research Scholar Track)
- Member of the Graduate Faculty
Steven Goldman, MD, is Professor of Medicine at the UA Sarver Heart Center. A native of Ohio, he received his undergraduate education at Cornell University and his Medical Doctorate from The University of Cincinnati Medical School. His residency training was at The University of Illinois, The University of Chicago and Stanford University. He received his cardiology training at the Pacific Medical Center in San Francisco, California. He came to The University of Arizona in 1975 from California.
Dr. Goldman is a member of the American Heart Association, the American College of Cardiology, the American Federation for Clinical Researchers, the American Physiologic Society, and the American Society for Pharmacology and Experimental Therapeutics. He has a VA Merit Review Grant entitled "Control of cellular function in heart failure." He is currently the Co-Chair of a VA cooperative study: Radial artery venus saphenous vein graft in CABG.
His major research interests are in cardiovascular physiology and pharmacology. To this end, he is actively investigating cell-based therapy for heart failure using stem cells seeded on a biodegradable patch as potential treatment for heart failure.
Dr. Goldman has won numerous awards for teaching over the years. In 2008 Dr. Goldman was named the Founders Day Speaker University of Arizona. This award is given each year to a faculty member with a long successful research career at the University of Arizona. In 2010 he was awarded the Charles W. Hall, Jr. Memorial Cardiology Fellowship Teaching Award. His research laboratory has received funding from the Veterans Administration, National Institutes of Health, American Heart Association, the Arizona Biomedical Research Commission, the biotechnology industry, and private foundations. His laboratory has supported the development of several young investigators.
- University of Cincinnati Medical School, Cincinnati, North Dakota, United States
- Cornell University, Ithaca, New York, United States
- SAVAHCS formerly Tucson VA Medical Center (1981 - 2013)
- University of Arizona, Tucson, Arizona (1981 - 1986)
- Tucson VA Medical Center (1977 - 1981)
- University of Arizona, Tucson, Arizona (1975 - 1981)
- Tucson VA Medical Center (1975 - 1981)
- United States Marine Corps, Navy. (1970 - 1972)
- The C. Leonard Pfeiffer Endowed Chair of Cardiovascular Research
- The C. Leonard Pfeiffer Endowed Chair, Spring 2018
- Cardiology Fellows Teaching/Mentoring Award
- Summer 2014
Licensure & Certification
- Arizona State Medical Doctor License (1975)
- Subspecialty Board of Cardiovascular Diseases (1977)
- Illinois State Medical License (1969)
- California State Medical Doctor License (1972)
- American Board of Internal Medicine (1973)
- Ohio Medical State License (1968)
No activities entered.
Directed ResearchPSIO 492 (Spring 2022)
Honors Independent StudyPSIO 399H (Spring 2022)
Honors Independent StudyPSIO 499H (Spring 2022)
Honors ThesisPSIO 498H (Spring 2022)
Independent StudyPSIO 399 (Spring 2022)
ResearchPS 900 (Spring 2022)
ThesisPS 910 (Spring 2022)
Directed ResearchPSIO 492 (Fall 2021)
Honors Independent StudyPSIO 399H (Fall 2021)
Honors ThesisPSIO 498H (Fall 2021)
Independent StudyPSIO 399 (Fall 2021)
ResearchPS 900 (Fall 2021)
ThesisPS 910 (Fall 2021)
Honors Independent StudyPSIO 399H (Spring 2021)
Honors Independent StudyPSIO 499H (Spring 2021)
Honors ThesisPSIO 498H (Spring 2021)
ResearchPS 900 (Spring 2021)
Directed ResearchPSIO 492 (Fall 2020)
DissertationPS 920 (Fall 2020)
Honors Independent StudyMCB 499H (Fall 2020)
Honors Independent StudyNSCS 399H (Fall 2020)
Honors Independent StudyPSIO 399H (Fall 2020)
Honors Independent StudyPSIO 499H (Fall 2020)
Honors ThesisPSIO 498H (Fall 2020)
Rsrch Meth Psio SciPS 700 (Fall 2020)
DissertationPS 920 (Summer I 2020)
Directed ResearchPSIO 492 (Spring 2020)
DissertationPS 920 (Spring 2020)
Honors Independent StudyPSIO 399H (Spring 2020)
Honors Independent StudyPSIO 499H (Spring 2020)
Honors ThesisBIOC 498H (Spring 2020)
ResearchPS 900 (Spring 2020)
Senior CapstoneBIOC 498 (Spring 2020)
Directed ResearchPSIO 492 (Fall 2019)
Honors Independent StudyPSIO 399H (Fall 2019)
Honors ThesisBIOC 498H (Fall 2019)
Rsrch Meth Psio SciPS 700 (Fall 2019)
Senior CapstoneBIOC 498 (Fall 2019)
Honors ThesisMCB 498H (Spring 2019)
Independent StudyPSIO 399 (Spring 2019)
Independent StudyPSIO 499 (Spring 2019)
ResearchPS 900 (Spring 2019)
Honors Independent StudyPSIO 399H (Fall 2018)
Honors Independent StudyPSIO 499H (Fall 2018)
Honors ThesisMCB 498H (Fall 2018)
Honors ThesisPSIO 498H (Fall 2018)
Directed ResearchPSIO 492 (Spring 2017)
Introduction to ResearchMCB 795A (Fall 2016)
Directed ResearchPSIO 492 (Spring 2016)
DissertationPSIO 920 (Spring 2016)
- Xenogiannis, I., Rangan, B. V., Uyeda, L., Banerjee, S., Edson, R., Bhatt, D. L., Goldman, S., Holmes, D. R., Rao, S. V., Shunk, K., Mavromatis, K., Ramanathan, K., Bavry, A. A., McFalls, E. O., Garcia, S., Thai, H., Uretsky, B. F., Latif, F., Armstrong, E., , Ortiz, J., et al. (2022). In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). The American journal of cardiology, 162, 24-30.More infoSaphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and angiographic characteristics of patients and lesions that did develop ISR with those who did not develop ISR during a median follow-up of 2.7 years in the DIVA study (NCT01121224). We also examined the ISR types using the Mehran classification. ISR developed in 119 out of the 575 DIVA patients (21%), with similar incidence among patients with drug-eluting stents and bare-metal stents (BMS) (21% vs 21%, p = 0.957). Patients in the ISR group were younger (67 ± 7 vs 69 ± 8 years, p = 0.04) and less likely to have heart failure (27% vs 38%, p = 0.03) and SVG lesions with Thrombolysis In Myocardial Infarction 3 flow before the intervention (77% vs 83%, p
- Chinyere, I. R., Bradley, P., Uhlorn, J., Eason, J., Mohran, S., Repetti, G. G., Daugherty, S., Koevary, J. W., Goldman, S., & Lancaster, J. J. (2021). Epicardially Placed Bioengineered Cardiomyocyte Xenograft in Immune-Competent Rat Model of Heart Failure. Stem cells international, 2021, 9935679.More infoHuman induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are under preclinical investigation as a cell-based therapy for heart failure post-myocardial infarction. In a previous study, tissue-engineered cardiac grafts were found to improve hosts' cardiac electrical and mechanical functions. However, the durability of effect, immune response, and properties of the tissue graft remained uncharacterized. This present study is aimed at confirming the graft therapeutic efficacy in an immune-competent chronic heart failure (CHF) model and providing evaluation of the properties of the tissue graft.
- Chinyere, I. R., Hutchinson, M., Moukabary, T., Koevary, J. W., Juneman, E., Goldman, S., & Lancaster, J. J. (2021). Modulating the Infarcted Ventricle's Refractoriness with an Epicardial Biomaterial. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 69(2), 364-370.More infoPatients diagnosed with heart failure with reduced ejection fraction (HFrEF) are at increased risk of monomorphic ventricular tachycardia (VT) and ventricular fibrillation. The presence of myocardial fibrosis provides both anatomical and functional barriers that promote arrhythmias in these patients. Propagation of VT in a reentrant circuit depends on the presence of excitable myocardium and the refractoriness of the circuit. We hypothesize that myocardial refractoriness can be modulated surgically in a model of HFrEF, leading to decreased susceptibility to VT.Male Sprague-Dawley rats were infarcted via permanent left coronary artery ligation. At 3 weeks post-infarction, engineered grafts composed of human dermal fibroblasts cultured into a polyglactin-910 biomaterial were implanted onto the epicardium to cover the area of infarction. Three weeks post-graft treatment, all rats underwent a terminal electrophysiologic study to compare monophasic action potential electroanatomic maps and susceptibility to inducible monomorphic VT.HFrEF rats (n=29) demonstrated a longer (p=0.0191) ventricular effective refractory period (ERP) and a greater (p=0.0394) VT inducibility compared with sham (n=7). HFrEF rats treated with the graft (n=12) exhibited no change in capture threshold (p=0.3220), but had a longer ventricular ERP (p=0.0029) compared with HFrEF. No statistically significant change in VT incidence was found between HFrEF rats treated with the graft and untreated HFrEF rats (p=0.0834).Surgical deployment of a fibroblast-containing biomaterial in a rodent ischemic cardiomyopathy model prolonged ventricular ERP as measured by programmed electrical stimulation. This hypothesis-generating study warrants additional studies to further characterize the antiarrhythmic or proarrhythmic effects of this novel surgical therapy.
- Chinyere, I. R., Moukabary, T., Hutchinson, M. D., Lancaster, J. J., Juneman, E., & Goldman, S. (2021). Progression of infarct-mediated arrhythmogenesis in a rodent model of heart failure. American journal of physiology. Heart and circulatory physiology, 320(1), H108-H116.More infoHeart failure (HF) post-myocardial infarction (MI) presents with increased vulnerability to monomorphic ventricular tachycardia (mmVT). To appropriately evaluate new therapies for infarct-mediated reentrant arrhythmia in the preclinical setting, chronologic characterization of the preclinical animal model pathophysiology is critical. This study aimed to evaluate the rigor and reproducibility of mmVT incidence in a rodent model of HF. We hypothesize a progressive increase in the incidence of mmVT as the duration of HF increases. Adult male Sprague-Dawley rats underwent permanent left coronary artery ligation or SHAM surgery and were maintained for either 6 or 10 wk. At end point, SHAM and HF rats underwent echocardiographic and invasive hemodynamic evaluation. Finally, rats underwent electrophysiologic (EP) assessment to assess susceptibility to mmVT and define ventricular effective refractory period (ERP). In 6-wk HF rats ( = 20), left ventricular (LV) ejection fraction (EF) decreased ( < 0.05) and LV end-diastolic pressure (EDP) increased ( < 0.05) compared with SHAM ( = 10). Ten-week HF ( = 12) revealed maintenance of LVEF and LVEDP ( > 0.05), ( > 0.05). Electrophysiology studies revealed an increase in incidence of mmVT between SHAM and 6-wk HF ( = 0.0016) and ERP prolongation ( = 0.0186). The incidence of mmVT and ventricular ERP did not differ between 6- and 10-wk HF ( = 1.0000), ( = 0.9831). Findings from this rodent model of HF suggest that once the ischemia-mediated infarct stabilizes, proarrhythmic deterioration ceases. Within the 6- and 10-wk period post-MI, no echocardiographic, invasive hemodynamic, or electrophysiologic changes were observed, suggesting stable HF. This is the necessary context for the evaluation of experimental therapies in rodent HF. Rodent model of ischemic cardiomyopathy exhibits a plateau of inducible monomorphic ventricular tachycardia incidence between 6 and 10 wk postinfarction.
- Xenogiannis, I., Zenati, M., Bhatt, D. L., Rao, S. V., Rodés-Cabau, J., Goldman, S., Shunk, K. A., Mavromatis, K., Banerjee, S., Alaswad, K., Nikolakopoulos, I., Vemmou, E., Karacsonyi, J., Alexopoulos, D., Burke, M. N., Bapat, V. N., & Brilakis, E. S. (2021). Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies. Circulation, 144(9), 728-745.More infoSaphenous vein grafts (SVGs) remain the most frequently used conduits in coronary artery bypass graft surgery (CABG). Despite advances in surgical techniques and pharmacotherapy, SVG failure rates remain high, often leading to repeat coronary revascularization. The no-touch SVG harvesting technique (minimal graft manipulation with preservation of vasa vasorum and nerves) reduces the risk of SVG failure, whereas the effect of the off-pump technique on SVG patency remains unclear. Use of buffered storage solutions, intraoperative graft flow measurement, careful selection of the target vessels, and physiological assessment of the native coronary circulation before CABG may also reduce the incidence of SVG failure. Perioperative aspirin and high-intensity statin administration are the cornerstones of secondary prevention after CABG. Dual antiplatelet therapy is recommended for off-pump CABG and in patients with a recent acute coronary syndrome. Intermediate (30%-60%) SVG stenoses often progress rapidly. Stenting of intermediate SVG stenoses failed to improve outcomes; hence, treatment focuses on strict control of coronary artery disease risk factors. Redo CABG is associated with higher perioperative mortality compared with percutaneous coronary intervention (PCI); hence, the latter is preferred for most patients requiring repeat revascularization after CABG. SVG PCI is limited by high rates of no-reflow and a high incidence of restenosis during follow-up. Drug-eluting and bare metal stents provide similar long-term outcomes in SVG PCI. Embolic protection devices reduce no-reflow and should be used when feasible. PCI of the corresponding native coronary artery is associated with better short- and long-term outcomes and is preferred over SVG PCI, if technically feasible.
- Chinyere, I. R., Hutchinson, M., Moukabary, T., Koevary, J. W., Juneman, E. B., Goldman, S., & Lancaster, J. (2020). Modulating the Infarcted Ventricle’s Refractoriness with an Epicardial Biomaterial.. Journal of Investigative Medicine.
- Goldman, S. (2020). Antiplatelet Agents Added to Aspirin: No Benefit for SVG Patency After CABG. Circulation, 142(19), 1808-1809.
- Latif, F., Uyeda, L., Edson, R., Bhatt, D. L., Goldman, S., Holmes, D. R., Rao, S. V., Shunk, K., Aggarwal, K., Uretsky, B., Bolad, I., Ziada, K., McFalls, E., Irimpen, A., Truong, H. T., Kinlay, S., Papademetriou, V., Velagaleti, R. S., Rangan, B. V., , Mavromatis, K., et al. (2020). Response by Latif et al to Letter Regarding Article, "Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial". Circulation. Cardiovascular interventions, 13(4), e009174.
- Chinyere, I. R., Hutchinson, M., Moukabary, T., Lancaster, J., Goldman, S., & Juneman, E. (2019). Monophasic action potential amplitude for substrate mapping. American journal of physiology. Heart and circulatory physiology, 317(4), H667-H673.More infoAlthough radiofrequency ablation has revolutionized the management of tachyarrhythmias, the rate of arrhythmia recurrence is a large drawback. Successful substrate identification is paramount to abolishing arrhythmia, and bipolar voltage electrogram's narrow field of view can be further reduced for increased sensitivity. In this report, we perform cardiac mapping with monophasic action potential (MAP) amplitude. We hypothesize that MAP amplitude (MAPA) will provide more accurate infarct sizes than other mapping modalities via increased sensitivity to distinguish healthy myocardium from scar tissue. Using the left coronary artery ligation Sprague-Dawley rat model of ischemic heart failure, we investigate the accuracy of in vivo ventricular epicardial maps derived from MAPA, MAP duration to 90% repolarization (MAPD), unipolar voltage amplitude (UVA), and bipolar voltage amplitude (BVA) compared with gold standard histopathological measurement of infarct size. Numerical analysis reveals discrimination of healthy myocardium versus scar tissue using MAPD ( = 0.0158) and UVA ( < 0.001, = 21). MAPA and BVA decreased between healthy and border tissue ( = 0.0218 and 0.0015, respectively) and border and scar tissue ( = 0.0037 and 0.0094, respectively). Contrary to our hypothesis, BVA mapping performed most accurately regarding quantifying infarct size. MAPA mapping may have high spatial resolution for myocardial tissue characterization but was quantitatively less accurate than other mapping methods at determining infarct size. BVA mapping's superior utility has been reinforced, supporting its use in translational research and clinical electrophysiology laboratories. MAPA may hold potential value for precisely distinguishing healthy myocardium, border zone, and scar tissue in diseases of disseminated fibrosis such as atrial fibrillation. Monophasic action potential mapping in a clinically relevant model of heart failure with potential implications for atrial fibrillation management.
- Lancaster, J., Koevary, J. W., Chinyere, I. R., Daugherty, S., Fox, K., & Goldman, S. (2019). Surgical treatment for heart failure: cell-based therapy with engineered tissue. Vessel Plus, 3, 34. doi:https://doi.org/10.20517/2574-1209.2019.16More infoarticle with embedded video
- Lancaster, J., Sanchez, P., Repetti, G., Juneman, E. B., Pandey, A., Royal Chinyere, I., Moukabary, T., LaHood, N., Daugherty, S., & Goldman, S. (2019). Human Induced Pluripotent Stem Cell Derived Cardiomyocyte Patch in Rats with Heart Failure.. Annals Thoracic Surgery, 1169-1177. doi:https://doi.org/10.1016/j.athoracsur.2019.03.099
- Ruttmann, E., Dietl, M., Feuchtner, G. M., Metzler, B., Bonaros, N., Taggart, D. P., Gaudino, M., Ulmer, H., & , R. I. (2019). Long-term clinical outcome and graft patency of radial artery and saphenous vein grafts in multiple arterial revascularization. The Journal of thoracic and cardiovascular surgery, 158(2), 442-450.More infoThe long-term benefits of multiple arterial revascularization (MAR) in coronary artery bypass grafting remain uncertain. The aim of this study was to investigate the clinical outcome, graft patency, and need for subsequent target revascularization of radial artery (RA) versus saphenous vein graft in patients undergoing MAR in both patient- and graft-specific analyses.
- Brilakis, E. S., Edson, R., Bhatt, D. L., Goldman, S., Holmes, D. R., Rao, S. V., Shunk, K., Rangan, B. V., Mavromatis, K., Ramanathan, K., Bavry, A. A., Garcia, S., Latif, F., Armstrong, E., Jneid, H., Conner, T. A., Wagner, T., Karacsonyi, J., Uyeda, L., , Ventura, B., et al. (2018). Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet (London, England), 391(10134), 1997-2007.More infoFew studies have examined the efficacy of drug-eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure compared with bare-metal stents (BMS) in patients undergoing stenting of de-novo SVG lesions. We assessed the risks and benefits of the use of DES versus BMS in de-novo SVG lesions.
- Chinyere, I. R., Moukabary, T., Goldman, S., & Juneman, E. (2018). Electrical and mechanical alternans during ventricular tachycardia with moderate chronic heart failure. Journal of electrocardiology, 51(1), 33-37.More infoA chronic heart failure (CHF) rat underwent epicardial programmed electrical stimulation (PES). Ventricular tachycardia (VT) developed during PES. Mechanical alternans was noted despite fixed tachycardia cycle length. Anti-tachycardia pacing attempts initiated a second VT that generated pulse intermittently and then degenerated into pulseless VT with electrical alternans.To our knowledge electrical and mechanical alternans have not been recorded in animal models of CHF during VT. The distinct events of mechanical alternans and electrical alternans may be indicative of progressively worsened calcium handling in the compromised cardiomyocytes.Although ion channel differences between rodents and humans exist, this work attempts to demonstrate this rat model's usefulness in understanding cardiac electrophysiology in CHF.
- Gaudino, M., Benedetto, U., Fremes, S., Biondi-Zoccai, G., Sedrakyan, A., Puskas, J. D., Angelini, G. D., Buxton, B., Frati, G., Hare, D. L., Hayward, P., Nasso, G., Moat, N., Peric, M., Yoo, K. J., Speziale, G., Girardi, L. N., & Taggart, D. P. (2018). Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery. The New England journal of medicine, 378(22), 2069-2077.More infoThe use of radial-artery grafts for coronary-artery bypass grafting (CABG) may result in better postoperative outcomes than the use of saphenous-vein grafts. However, randomized, controlled trials comparing radial-artery grafts and saphenous-vein grafts have been individually underpowered to detect differences in clinical outcomes. We performed a patient-level combined analysis of randomized, controlled trials to compare radial-artery grafts and saphenous-vein grafts for CABG.
- Lancaster, J. J., Koevary, J. W., Chinyere, I. R., & Goldman, S. (2018). The Promise of Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Treat Heart Failure. Circulation. Heart failure, 11(10), e005425.
- Ortiz, F., Mbai, M., Adabag, S., Garcia, S., Nguyen, J., Goldman, S., Ward, H. B., Kelly, R. F., Carlson, S., Holman, W. L., & McFalls, E. O. (2018). Utility of nuclear stress imaging in predicting long-term outcomes one-year post CABG Surgery. Journal of Nuclear Cardiology : official publication of the American Society of Nuclear Cardiology. doi:10.1007/s12350-018-01469-yMore infoEarly MPI after CABG is currently considered rarely appropriate in asymptomatic patients. This study aimed to identify prognostic value of nuclear stress-imaging post-CABG.
- Brilakis, E. S., Banerjee, S., Edson, R., Shunk, K., Goldman, S., Holmes, D. R., Bhatt, D. L., Rao, S. V., Smith, M. W., Sather, M., Colling, C., Kar, B., Nielsen, L., Conner, T., Wagner, T., Rangan, B. V., Ventura, B., Lu, Y., Holodniy, M., & Shih, M. C. (2017). Rationale and design of the Drug-Eluting Stents vs Bare-Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial. Clinical cardiology, 40(11), 946-954.More infoVA Cooperative Studies Program #571 (DIVA) was designed to evaluate the efficacy of drug-eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure when compared with bare-metal stents (BMS) in participants undergoing stenting of de novo SVG lesions. Participants undergoing clinically indicated stenting of de novo SVG lesions were randomized in a 1:1 ratio to DES or BMS. Randomization was stratified by presence/absence of diabetes mellitus and the number of target SVG lesions (1 vs ≥2) within each participating site. At sites that did not routinely administer 12-months of dual antiplatelet therapy after SVG stenting participants without acute coronary syndromes received 1 month of open-label clopidogrel, followed by 11 months of clopidogrel for those assigned to DES and 11 months of placebo for those assigned to BMS. The primary endpoint was the 12-month incidence of target-vessel failure (defined as the composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization). Secondary endpoints included the incidence of other clinical endpoints and the incremental cost-effectiveness of DES relative to BMS. Due to lower-than-anticipated target-vessel failure rates, target enrollment was increased from 519 to 762. The study had randomized 599 participants when recruitment ended in December 2015. The DIVA trial will provide clarity on the appropriate stent type for de novo SVG lesions.
- Chinyere, I., Moukabary, T., Goldman, S., & Juneman, E. B. (2017). Electrical and Mechanical Alternans during Ventricular Tachycardia with Moderate Chronic Heart Failure. Journal of Electrocardiography. doi:doi.org/10.1016/j.jelectrocard.2017.09.002
- Gaudino, M., Alexander, J. H., Bakaeen, F. G., Ballman, K., Barili, F., Calafiore, A. M., Davierwala, P., Kappetein, P., Lorusso, R., Mylotte, D., Pagano, D., Ruel, M., Schwann, T., Suma, H., Taggart, D. P., Tranbaugh, R. F., Fremes, S., & Goldman, S. (2017). Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and study protocol. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 52(6), 1031-1040.More infoThe primary hypothesis of the ROMA trial is that in patients undergoing primary isolated non-emergent coronary artery bypass grafting, the use of 2 or more arterial grafts compared with a single arterial graft (SAG) is associated with a reduction in the composite outcome of death from any cause, any stroke, post-discharge myocardial infarction and/or repeat revascularization.
- Goldman, S. (2017). Tucson Tech: University of Arizona startup advances living heart patch. Arizona Daily Star.More infohttp://tucson.com/business/tucson/tucson- tech-university-of-arizona-startup-advances-living-heart-patch/article_2149e262-c9f9- 5609-877f-2615ac432ee6.html
- Pandey, A. C., Lancaster, J. J., Harris, D., Goldman, S., & Juneman, E. B. (2017). Cellular Therapeutics for Heart Failure: Focus on Mesenchymal Stem Cells. Stem Cell International, 2017, 12. doi:doi.org/10.1155/2017/9640108
- Sanchez, P., Lancaster, J. J., Weigand, K., Mohran, S. E., Goldman, S., & Juneman, E. (2017). Doppler Assessment of Diastolic Function Reflect the Severity of Injury in Rats With Chronic Heart Failure. Journal of cardiac failure, 23(10), 753-761.More infoFor chronic heart failure (CHF), more emphasis has been placed on evaluation of systolic as opposed to diastolic function. Within the study of diastology, measurements of left ventricular (LV) longitudinal myocardial relaxation have the most validation. Anterior wall radial myocardial tissue relaxation velocities along with mitral valve inflow (MVI) patterns are applicable diastolic parameters in the differentiation between moderate and severe disease in the ischemic rat model of CHF. Myocardial tissue relaxation velocities correlate with traditional measurements of diastolic function (ie, hemodynamics, Tau, and diastolic pressure-volume relationships).
- Chinyere, I., Weigand, K., Moukabary, T., Witte, R. S., Lancaster, J., Goldman, S., & Juneman, E. B. (2016). Model of Induced Ventricular Tachycardia and Cardiac Electrophysiological Mapping. Circulation Research, 119(Supl 1), A 71.
- Lancaster, J., Chinyere, I., Kim, B. N., Daugherty, S., Kim, S., Jokerst, C., Avery, R., Larson, B., Lancaster, L. D., Juneman, E. B., & Goldman, S. (2016). . Feasibility and Testing of a Human Induced Pluripotent Stem Cell Derived Cardiac Patch in a Pre-clinical Swine Model of CHF. Circulation Research, 119(Supl 1), A 205.
- Lancaster, J., Pandey, A., Weigand, K., Bahl, J., Juneman, E. B., & Goldman, S. (2016). Implantation of an induced pluripotent stem cell derived cardiomyocyte tissue engineered patch improves left ventricular function and electromechanical coupling in rats with heart failure. Journal of Cardiac Failure, 22(8), S 123. doi:http://dx.doi.org/10.1016/j.cardfail.2016.06.383
- Mohran, S., Lancaster, J., Sanchez, P., Goldman, S., & Juneman, E. B. (2016). Differentiation of Moderate and Severe Ischemic Heart Failure by Invasive and Non-invasive Assessments of Diastolic Function in a Rat Model of Chronic Heart Failure. Circulation Research, 119(Supl 1), A48.
- Weigand, K., Witte, R., Moukabary, T., Chinyere, I., Lancaster, J., Pierce, M. K., Goldman, S., & Juneman, E. (2016). In-vivo Electrophysiological Study of Induced Ventricular Tachycardia in Intact Rat Model of Chronic Ischemic Heart Failure. IEEE transactions on bio-medical engineering.More infoThe objective of this study was to define the clinical relevance of in-vivo electrophysiologic (EP) studies in a rat model of chronic ischemic heart failure (CHF).
- Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., Holman, R. R., & , T. S. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 373(3), 232-42.More infoData are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.
- Gupta, A., Gupta, G., Kim, T. Y., Shi, G., Weigand, K., Batai, K., Fleming, I., Kanady, J., Rutledge, C., Nair, N., Groth, J., Juneman, E. B., Goldman, S., Indik, J. H., Hillery, C., Garcia, J. G., Machado, R. F., Kittles, R., Dudley, S. C., , Choi, B., et al. (2018). IL-18 is a novel mediator of prolonged QTc and ventricular arrhythmias associated with Sickle Cell Disease. Proceedings of the National Academy of Sciences.
- Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., Emanuele, N. V., & , V. I. (2015). Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. The New England journal of medicine, 372(23), 2197-206.More infoThe Veterans Affairs Diabetes Trial previously showed that intensive glucose lowering, as compared with standard therapy, did not significantly reduce the rate of major cardiovascular events among 1791 military veterans (median follow-up, 5.6 years). We report the extended follow-up of the study participants.
- Lancaster, J. J., Juneman, E., Arnce, S. A., Johnson, N. M., Qin, Y., Witte, R., Thai, H., Kellar, R. S., Ek Vitorin, J., Burt, J., Gaballa, M. A., Bahl, J. J., & Goldman, S. (2014). An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 33(4), 438-45.More infoVarying strategies are currently being evaluated to develop tissue-engineered constructs for the treatment of ischemic heart disease. This study examines an angiogenic and biodegradable cardiac construct seeded with neonatal cardiomyocytes for the treatment of chronic heart failure (CHF).
- O'Donoghue, M. L., Braunwald, E., White, H. D., Steen, D. P., Lukas, M. A., Tarka, E., Steg, P. G., Hochman, J. S., Bode, C., Maggioni, A. P., Im, K., Shannon, J. B., Davies, R. Y., Murphy, S. A., Crugnale, S. E., Wiviott, S. D., Bonaca, M. P., Watson, D. F., Weaver, W. D., , Serruys, P. W., et al. (2014). Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA, 312(10), 1006-15.More infoLipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.
- Holman, W. L., Davies, J. E., Lin, J. Y., Wang, Y., Goldman, S., Bakaeen, F. G., Kelly, R., Fremes, S. E., Lee, K. K., Wagner, T. H., Sethi, G. K., & , V. C. (2013). Consequences of radial artery harvest: results of a prospective, randomized, multicenter trial. JAMA surgery, 148(11), 1020-3.More infoTo date, no study has defined the consequences of radial artery harvest based on a large number of patients in a prospective randomized trial.
- Garcia, S., Rider, J. E., Moritz, T. E., Pierpont, G., Goldman, S., Larsen, G. C., Shunk, K., Littooy, F., Santilli, S., Rapp, J., Reda, D. J., Ward, H. B., & McFalls, E. O. (2011). Preoperative coronary artery revascularization and long-term outcomes following abdominal aortic vascular surgery in patients with abnormal myocardial perfusion scans: a subgroup analysis of the coronary artery revascularization prophylaxis trial. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 77(1), 134-41.More infoAbdominal aortic operations have the highest perioperative cardiac risk. To test the impact of preoperative coronary artery revascularization (PR) in this high-risk subset, a post hoc analysis was performed in patients undergoing aortic surgery within the Coronary Artery Revascularization Prophylaxis (CARP) trial.
- Goldman, S., Sethi, G. K., Holman, W., Thai, H., McFalls, E., Ward, H. B., Kelly, R. F., Rhenman, B., Tobler, G. H., Bakaeen, F. G., Huh, J., Soltero, E., Moursi, M., Haime, M., Crittenden, M., Kasirajan, V., Ratliff, M., Pett, S., Irimpen, A., , Gunnar, W., et al. (2011). Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. JAMA, 305(2), 167-74.More infoArterial grafts are thought to be better conduits than saphenous vein grafts for coronary artery bypass grafting (CABG) based on experience with using the left internal mammary artery to bypass the left anterior descending coronary artery. The efficacy of the radial artery graft is less clear.
- Gottlieb, S. S., Ticho, B., Deykin, A., Abraham, W. T., Denofrio, D., Russell, S. D., Chapman, D., Smith, W., Goldman, S., & Thomas, I. (2011). Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure. Journal of clinical pharmacology, 51(6), 899-907.More infoPrevious studies suggest that adenosine A₁ receptor antagonists may promote natriuresis without deleterious effects on renal function. This study evaluated renal and hemodynamic effects as well as safety, pharmacokinetics, and tolerability of BG9928, a selective adenosine A₁-receptor antagonist, in patients with heart failure. In this multicenter, randomized, double-blind, placebo-controlled, dose-escalation study, 33 patients received a single dose of BG9928 (0.03, 0.3, 1.0, or 3.0 mg/kg) or placebo intravenously. Change from baseline in urinary sodium excretion for the 8-hour postdose interval was greater for all dosing groups versus placebo. The 0.03-mg/kg and 0.3-mg/kg groups had significant reductions in body weight versus placebo (-0.8 kg, -1.1 kg, 0.3 kg, respectively; P < 005). No changes in creatinine clearance or hemodynamic parameters were observed among any of the BG9928 groups versus placebo. However, pulmonary capillary wedge pressure tended to decrease and correlated with weight loss. Across the range of doses studied, pharmacokinetic parameters were linear and predictable. One patient who received the highest dose (3.0 mg/kg) developed seizures, and no further patients received that dose. Single intravenous BG9928 doses of up to 1.0 mg/kg were well tolerated and increased sodium excretion without worsening renal function. Further studies are needed to determine the clinical benefit of adenosine A₁ receptor antagonism.
- Kellar, R. S., Lancaster, J. J., Thai, H. M., Juneman, E., Johnson, N. M., Byrne, H. G., Stansifer, M., Arsanjani, R., Baer, M., Bebbington, C., Flashner, M., Yarranton, G., & Goldman, S. (2011). Antibody to granulocyte macrophage colony-stimulating factor reduces the number of activated tissue macrophages and improves left ventricular function after myocardial infarction in a rat coronary artery ligation model. Journal of cardiovascular pharmacology, 57(5), 568-74.More infoGranulocyte macrophage colony-stimulating factor (GM-CSF) promotes infarct expansion and inappropriate collagen synthesis in a myocardial infarction (MI). This study was designed to determine if treatment with anti-GM-CSF will inhibit macrophage migration, preserve function, and limit left ventricular (LV) remodeling in the rat coronary artery ligation model. Treatment with a monoclonal antibody to GM-CSF (5 mg/kg) was initiated 24 hours before coronary artery ligation and continued every 3 days for 3 weeks. Left coronary arteries of rats were ligated, animals were recovered, and cardiac function was evaluated 3 weeks postligation. Tissue samples were processed for histochemistry. Anti-GM-CSF treatment increased LV ejection fraction (37 ± 3% vs 47 ± 5%) and decreased LV end systolic diameter (0.75 ± 0.12 vs 0.59 ± 0.05 cm) with no changes in LV systolic pressure (109 ± 4 vs 104 ± 5 mm Hg), LV end diastolic pressure (22 ± 4 vs 21 ± 2 mm Hg), LV end diastolic diameter (0.96 ± 0.04 vs 0.92 ± 0.05 cm), or the time constant of LV relaxation tau (25.4 ± +2.4 vs 22.7 ± 1.4 milliseconds) (P < 0.05). Significantly lower numbers of tissue macrophages and significant reductions in infarct size were found in the myocardium of antibody-treated animals (81 ± 21.24 vs 195 ± 31.7 positive cells per 0.105 mm, compared with controls. These findings suggest that inhibition of macrophage migration may be beneficial in the treatment of heart failure after MI.
- Shanmugasundaram, M., Ram, V., Jayasuria, S., Dewar, J., Boyella, R., Kalra, N., & Goldman, S. (2011). Zotarolimus Drug Eluting Stents in Percutaneous Coronary Revascularization Compared to 1st Generation DES in High Risk Patients with Left Main Coronary Artery Disease.. Journal of Investigative Medicine, 59(1), 88-217.
- Shanmugasundaram, M., Ram, V., Jayasuria, S., Dewar, J., Nguyen, J., Boyella, R., & Goldman, S. (2011). The Effect of IVUS Guidance on Clinical Outcomes in Percutaneous Revascularization compared to Coronary Artery Bypass Grafting among High Risk Patients with Left Main Coronary Artery Disease. Journal of Investigative Medicine, 59(1), 888-217.
- Wagner, T. H., Holman, W., Lee, K., Sethi, G., Ananth, L., Thai, H., & Goldman, S. (2011). The generalizability of participants in Veterans Affairs Cooperative Studies Program 474, a multi-site randomized cardiac bypass surgery trial. Contemporary clinical trials, 32(2), 260-6.More infoThe Department of Veterans Affairs (VA) Cooperative Studies Program (CSP) initiated a multi-site randomized trial (CSP 474) to determine graph patency between radial artery or saphenous vein grafts in coronary artery bypass surgery (CABG). In this paper, we describe the study and compare participants' baseline characteristics to non-participants who received CABG surgery in the VA.
- Brilakis, E. S., Wang, T. Y., Rao, S. V., Banerjee, S., Goldman, S., Shunk, K., Kar, B., Holmes, D. R., Dai, D., Chin, C. T., Harding, T. M., & Roe, M. T. (2010). Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. JACC. Cardiovascular interventions, 3(10), 1068-73.More infoWe examined a large registry to determine the frequency and factors associated with drug-eluting stents (DES) use in saphenous vein graft (SVG) in contemporary practice.
- Garcia, S., Murray, S. T., Moritz, T. E., Pierpont, G., Goldman, S., Larsen, G. C., Littooy, F., Ward, H. B., & McFalls, E. O. (2010). Culprit coronary lesions requiring percutaneous coronary intervention after vascular surgery often arise from in-stent restenosis of bare metal stents. Annals of vascular surgery, 24(5), 596-601.More infoThe natural history of coronary artery disease (CAD) after vascular surgery is poorly defined. The aim of this study was to determine the temporal change of coronary artery lesions requiring revascularization with a percutaneous coronary intervention (PCI) after elective vascular surgery and to determine the utility of preoperative biomarkers on predicting those patients at risk for new coronary lesions.
- Lancaster, J., Juneman, E., Hagerty, T., Do, R., Hicks, M., Meltzer, K., Standley, P., Gaballa, M., Kellar, R., Goldman, S., & Thai, H. (2010). Viable fibroblast matrix patch induces angiogenesis and increases myocardial blood flow in heart failure after myocardial infarction. Tissue engineering. Part A, 16(10), 3065-73.More infoThis study examines a viable biodegradable three-dimensional fibroblast construct (3DFC) in a model of chronic heart failure. The viable fibroblasts, cultured on a vicryl mesh, secrete growth factors that stimulate angiogenesis.
- Thal, S., Moukaberry, T., Boyella, R., Shanmugasundaram, M., Pierce, M., Thai, H., & Goldman, S. (2010). The Relation between warfarin, aspirin and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation. Pacing and Clinical Electrophysiology, 33(4), 385-388. doi:10.1111/j.1540-8159.2009.02674.x
- Zakharova, L., Mastroeni, D., Mutlu, N., Molina, M., Goldman, S., Diethrich, E., & Gaballa, M. A. (2010). Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovascular research, 87(1), 40-9.More infoCell-based therapy for myocardial infarction (MI) holds great promise; however, the ideal cell type and delivery system have not been established. Obstacles in the field are the massive cell death after direct injection and the small percentage of surviving cells differentiating into cardiomyocytes. To overcome these challenges we designed a novel study to deliver cardiac progenitor cells as a cell sheet.
- Chinyere, I. R., Weigand, K., Moukabary, T., Witte, R. S., Chu, M., Novak, S., Hutchinson, M., Lancaster, J., Gregorio, C. C., Goldman, S., & Juneman, E. B. (2018, spring). Mapping and Inducing Ventricular Tachycardia in Cardiomyopathic Animal Models. Circ Res. San Antonio, TX: 2018 Circ Res 121:A86.
- Lancaster, J., Koevary, J. W., Chinyere, I. R., Juneman, E. B., & Goldman, S. (2017, Summer). Cardiac Grafts Engineered from human iPSC Ventricular Pure or Heterogeneous Cardiomyocytes Display Synchronous Spontaneous Contraction and Reduces Ventricular Tachycardia in Rats with Chronic Heart Failure. J Cardiac Failure. Dallas, TX.
- Goldman, S. (2020, Winter). No Benefit SVG Patency Aspirin and Ticagrelor - Editorial. Circulation.